Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles and rubella vaccine (live)
- Development stage
- Unknown
- Lead developer
- Shenzhen Kangtai Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The Measles and Rubella Combined Vaccine (Live) is a bivalent, live attenuated vaccine developed by Shenzhen Kangtai Biological Products (also known as Shenzhen Kangde). It is designed to provide active immunity against both measles and rubella in a single administration. The vaccine contains attenuated strains of the *Measles morbillivirus* and *Rubella virus*, which stimulate the production of protective antibodies without causing the full-blown disease. Approved and launched in China in September 2013, it is primarily indicated for the prevention of measles and rubella in children, typically administered via subcutaneous injection. This combination vaccine simplifies the immunization schedule and improves coverage for these two highly contagious viral infections.
- Brand names
- MR-Vac
- Other names
- Measles-Rubella VaccineMR vaccineCombined measles and rubella vaccineLive attenuated measles-rubella vaccineMeasles and Rubella Combined Vaccine
02
Targets
Rubella virus E1 envelope glycoproteinMeasles virus fusion glycoproteinMV-H (Measles virus hemagglutinin protein)
Beyond the preview
Go deeper on measles and rubella vaccine (live).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles and rubella vaccine (live).